Table 3. Comparison of various neutrophils-associated inflammatory mediators in CRSwNP according to disease control status.
| No. of subjects (n = 76) | Disease control status | |
|---|---|---|
| Controlled group (n = 48) | Refractory group (n = 28) | |
| HNE-positive cells | 9.75 (5.4–21) | 23.5 (16.75–45.75)* |
| HNE (ng/mg) | 4.35 (4.00–5.64) | 76.04 (50.84–86.12)* |
| MPO (ng/mg) | 63.74 (34.38–89.36)* | 34.24 (19.91–48.33) |
| CXCL1 (ng/mg) | 0.75 (0.38–1.29) | 0.77 (0.44–1.65) |
| CXCL8 (pg/mg) | 177 (76–296) | 159 (71–391) |
| GM-CSF (pg/mg) | 0.24 (0.19–0.60) | 0.21 (0.16–0.39) |
| IFN-γ (pg/mg) | 6.01 (1.04–8.14) | 3.31 (0.52–6.91) |
| IL-1α (pg/mg) | 2.58 (1.55–3.74) | 2.40 (1.10–3.54) |
| IL-1β (pg/mg) | 0.30 (0.23–2.74) | 0.84 (0.28–2.43) |
| IL-1Ra (ng/mg) | 4.38 (2.14–13.14) | 3.49 (2.24–10.62) |
| IL-6 (pg/mg) | 5.64 (2.05–17.51) | 6.84 (2.61–17.34) |
| IL-17A (pg/mg) | 0.55 (0.46–0.78) | 0.64 (0.49–1.81) |
| IL-18 (pg/mg) | 27.40 (19.93–42.13)* | 18.45 (12.49–24.09) |
| IL-22 (pg/mg) | 0.78 (0.68–1.03) | 0.86 (0.63–3.53) |
| IL-23 (pg/mg) | 11.61 (9.76–20.22) | 12.13 (8.44–18.21) |
| IL-36α (pg/mg) | 9.36 (0.49–94) | 44.84 (2.77–132.73)* |
| TNF-α (pg/mg) | 0.18 (0–0.66) | 0.23 (0–0.89) |
| MMP-9 (ng/mg) | 12.46 (6.80–20.21) | 17.20 (10.88–28.23) |
| OSM (pg/mg) | 288 (238–373) | 246 (162–316) |
Value is presented as median with IQR.
CRSwNP, chronic rhinosinusitis with nasal polyps; HNE, human neutrophil elastase, MPO, myeloperoxidase; CXCL, chemokine (C-X-C motif) ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; MMP, matrix metallopeptidase; OSM, oncostatin M.
*Means P value < 0.05.